ProteoNic unveils 2G UNic transposon platform for enhanced biologics production
Dutch biotechnology company ProteoNic has announced the commercial launch of its 2G UNic transposon platform, combining established vector technology with proprietary transposon systems to improve cell line productivity and reduce development timelines for complex biologics manufacturing.
Dual-system approach addresses manufacturing challenges
The new platform integrates ProteoNic’s proven 2G UNic vector technology with a proprietary transposon system, designed for application across mammalian and yeast cell platforms. The technology targets production challenges associated with complex biologics and difficult-to-express proteins.
ProteoNic has simultaneously expanded its 2G UNic vector technology to support existing third-party transposon systems, enabling customers to enhance established workflows without changing underlying platforms. The modified technology maintains compatibility across all transposon systems, regardless of cell type or product class.
Performance data shows significant productivity gains
Laboratory testing demonstrates the platform delivers more than two-fold increases in production titres, supporting manufacturing levels up to 10 g/L. These improvements translate to reduced manufacturing costs and enhanced productivity for complex biologics production.
“We are proud to announce the development and launch of our novel 2G UNic transposon platform that takes productivity, flexibility, and ease of use in cell line generation to the next level,” said Frank Pieper, CEO of ProteoNic. “By also expanding our premium 2G UNic vector technology to support other transposon systems, we can now offer customers maximum flexibility.”
Applications extend beyond therapeutic proteins
The platform shows applications in therapeutic antibody and protein production, with additional promise for stable producer cell line generation in cell and gene therapy. This capability broadens opportunities for biopharmaceutical partners across multiple therapeutic modalities.
Commercial availability follows industry evaluation
The launch follows successful evaluations with industry partners, confirming platform performance in manufacturing environments. Both the 2G UNic transposon platform and expanded vector technology capabilities
are now available for licensing to biopharmaceutical companies and contract development and manufacturing organisations worldwide.
ProteoNic presented the platform at BioProcess International during Biotech Week Boston, demonstrating productivity improvements for complex biologics development. The technology addresses gene expression challenges in mammalian production systems whilst maintaining stability through extended production
cycles.
For more information, visit: https://proteonic.nl/2g-unic-transposon-technology/
Digital issue: Please click here for more information
